Neurocrine Biosciences (NBIX) EBT (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly EBT of $162.2 million for Q2 2026, up 1.69% year-over-year from $159.5 million in Q2 2025, and down 34.28% on a QoQ basis from $246.8 million in Q1 2026.
Neurocrine Biosciences (NBIX) EBT (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported EBT for 17 years, with the latest figure at $162.2 million in Q2 2026.
- EBT for Q2 2026 came in at $162.2 million, up 1.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $940.2 million (up 78.37% YoY), and the FY2025 annual result was $705.4 million, up 45.14% from the prior year.
- EBT fell to $162.2 million in Q2 2026, from $246.8 million in the prior quarter.
- Over five years, EBT peaked at $291.8 million in Q3 2025 and troughed at -$103.3 million in Q1 2023.
- A 5-year average of $119.2 million and a median of $119.8 million in 2022 frame the typical range for EBT.
- The widest annual swing landed in 2023, when EBT plunged 582.71%; it then soared 1578.91% in 2026.
- A 5-year view of EBT shows it stood at $117.9 million in 2022, then surged by 68.11% to $198.2 million in 2023, then fell by 17.96% to $162.6 million in 2024, then jumped by 47.23% to $239.4 million in 2025, then plunged by 32.25% to $162.2 million in 2026.
- Per Business Quant data, the three most recent EBT figures were $162.2 million in Q2 2026, $246.8 million in Q1 2026, and $239.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -455.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 372.70 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | -64.00 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 162.20 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | -4.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 56.00 Mn |
| 10 | HUTCHMED (China) | 10.92 Bn | 9.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.20 Mn |
| Mar 31, 2026 | 246.80 Mn |
| Dec 31, 2025 | 239.40 Mn |
| Sep 30, 2025 | 291.80 Mn |
| Jun 30, 2025 | 159.50 Mn |
| Mar 31, 2025 | 14.70 Mn |
| Dec 31, 2024 | 162.60 Mn |
| Sep 30, 2024 | 190.30 Mn |
| Jun 30, 2024 | 98.60 Mn |
| Mar 31, 2024 | 34.50 Mn |
| Dec 31, 2023 | 198.20 Mn |
| Sep 30, 2023 | 115.60 Mn |
| Jun 30, 2023 | 121.60 Mn |
| Mar 31, 2023 | -103.30 Mn |
| Dec 31, 2022 | 117.90 Mn |
| Sep 30, 2022 | 97.90 Mn |
| Jun 30, 2022 | -23.30 Mn |
| Mar 31, 2022 | 21.40 Mn |
| Dec 31, 2021 | -13.80 Mn |
| Sep 30, 2021 | 30.50 Mn |